ClinicalTrials.gg
Enrolling by invitationNCT06872619RegisterPROSUpdated Aug 21, 2026

RegisterPROS - A Registry for Prostate Cancers

An observational study in Prostate Cancer (Adenocarcinoma), Prostate Biopsy and Prostatectomy, sponsored by Wren Laboratories LLC. Enrolling by invitation at 1 site in Germany. Open to male participants aged 45 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Wren Laboratories LLC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
45 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Prostatic Neoplasms with a site in Germany — 70 open to participants now, 116 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.

Planned enrollment
17th of 61
1,000 · median 461
Started
2020
with 16 others
Observational
61 of 333
20 open now
Primary completion
2028-12
later than 81 of 115 live
Registered
298th of 333
by date

Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 17th largest by planned enrollment of the 61 observational ones that give a count, is one of 17 that started in 2020, is one of 61 observational ones, reaches primary completion later than 81 of the 115 other live ones, and was the 298th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years to 100 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Prostatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT). Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive tests that can detect prostate cancer disease activity. A second challenge is to evaluate the effectiveness of such biomarkers during the natural history of this disease (e.g., active surveillance). A third aim is to identify whether molecular markers can predict response to different therapies (either pre-treatment, or early on during the first few cycles of a therapy). RegisterPROS registry aims at collecting data and blood samples from patients being evaluated for PCa disease. Data will be entered prospectively and anonymized after informed consent. All physicians who treat PCas are invited to participate to the registry. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.

Read the detailed description

Background: Survival of PCas is linked to early and accurate diagnoses of aggressive disease (GG2-5) and effective detection of disease progression and/or recurrence (minimal residual disease or treatment failure). Tissue based molecular markers have been developed and have utility (e.g., OncoType Dx). Blood-based markers e.g., ARV-7 detection may also have utility. However, PSA (and changes in levels from baseline) are considered the current standard of care. Molecular markers e.g., PROSTest, have been developed but little is known about the utility of these markers in clinical practice. Objective: To systematically and prospectively collect clinical information and samples (blood and saliva) from PCas in Europe, Africa, Caribbean and the USA based a histologically confirmed diagnosis. Methods: PCas will be enrolled and followed up following informed consent. Data will be entered prospectively and anonymized. Patient history are completed by contributing physicians and samples are collected for analysis. All information will be transferred to a database. Evaluation of treatment modalities and patient outcomes (e.g. disease recurrence) will be assessed at follow-up times. The primary objectives of the project are to:

1a) assess diagnostic accuracy of molecular-based blood tests e.g., PROSTest.

  1. b) evaluate utility of molecular-based tests e.g., PROSTest to monitor PCa patients (active surveillance or on treatment).

    The secondary objectives of the project include:

  2. a) assess utility of molecular-based tools to detect disease recurrence

2b) examine whether these tools can predict response to different therapies

Analyses will include:

  1. Descriptive statistical analyses including demographics, histology and grading, treatment types.
  2. Clinical follow-up and blood chemistry (PSA) and molecular results.
  3. Correlation analyses between blood results and clinical data. This will include assessment of the time at which the results significantly (and consistently) increases and the time of tumor recurrence and an evaluation whether the change in blood results is predictive of disease recurrence and/or treatment efficacy.
03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
  • Prostate Biopsy
  • Prostatectomy
  • Radioligand
  • Chemotherapy
  • Androgen Deprivation Therapy
  • PSA
04

Who can participate

Ages eligible
45 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with a histologically confirmed diagnosis of a prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects

Exclusion criteria

Exclusion Criteria:

  • Female
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Prostate cancer subjects

    Subjects at risk or who have a histological confirmation of prostate cancer disease (all Gleason grades, all stages including castration resistant disease). Interventions include ADT, chemotherapy and RLT

    Device: PROSTest

Interventions

  • DevicePROSTest

    Multianalyte Algorithm Analysis of circulating prostate cancer transcripts

06

What researchers measure

Primary outcomes

  1. PCa diagnosis

    Histology confirmed prostate cancer disease

    Time frame: 5 years

  2. Surveillance

    Natural progression of disease

    Time frame: 10 years

Secondary outcomes

  1. Minimal residual disease

    Detection of MRD

    Time frame: 10 years

  2. Therapy efficacy

    Treatment response assessment

    Time frame: 10 years

07

Study locations

1 site
08

References and documents

Publications

  • Modlin IM, Kidd M, Drozdov IA, Boegemann M, Bodei L, Kunikowska J, Malczewska A, Bernemann C, Koduru SV, Rahbar K. Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood. Prostate. 2024 Jun;84(9):850-865. doi: 10.1002/pros.24704. Epub 2024 Apr 3. PubMed 38571290 ↗
  • Rosin RD, Haynes A, Kidd M, Drozdov I, Modlin I, Halim A. Evaluation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection and follow-up in a Caribbean population. Cancer Epidemiol. 2024 Oct;92:102642. doi: 10.1016/j.canep.2024.102642. Epub 2024 Aug 9. PubMed 39121520 ↗
  • Rahbar K, Kidd M, Prasad V, David Rosin R, Drozdov I, Halim A. Clinical Sensitivity and Specificity of the PROSTest in an American Cohort. Prostate. 2025 May;85(6):558-566. doi: 10.1002/pros.24858. Epub 2025 Jan 21. PubMed 39838708 ↗
  • Rahbar K, Schlack K, Bogemann M. Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study. BMC Cancer. 2025 Jul 10;25(1):1159. doi: 10.1186/s12885-025-14549-3. PubMed 40640763 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Dec 2028, 107 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 107 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 12, 2025
StartActual
Jan 15, 2020
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 15, 2030
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06872619
Lead sponsor
Wren Laboratories LLC
Collaborators
Münster University Hospital, Germany
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Jan 15, 2020
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 15, 2030 (estimated)
Last update
Aug 21, 2026

Study contacts

Abdel Halim, PhD, PharmD
study director · Wren Laboratories
Kambiz Rahbar, MD
principal investigator · Munster University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion